Introduction
Hypertensive disorders of pregnancy are important contributors to the global burden of maternal mortality, accounting for 12.9 and 14% of maternal deaths in highincome countries and low-and middle-income countries (LMICs), respectively (1) . Preeclampsia, defined as hypertension with proteinuria during pregnancy, complicates 4-5% of pregnancies (2) (3) (4) . This multisystemic disorder can have a range of complications including eclampsia, placental abruption, preterm birth, HELLP syndrome (hemolysis, elevated liver enzymes, low platelets), cerebrovascular accident, acute renal injury, and respiratory distress syndrome (2, 4) . Eclampsia is defined as generalized fits in a patient with preeclampsia without previous history of epilepsy (5) . LMICs have higher rates of eclampsia, where it complicates 16-69 births per 10 000, compared with Europe where is complicates 2-3 births per 10 000 (6). Lack, or low utilization, of antenatal care and inadequate hospital services are key reasons for this contrast (6, 7) . Timely identification and treatment of preeclampsia at a global scale would significantly reduce this disparity (8, 9) .
For nearly a century, magnesium sulfate has been used for the management of preeclampsia and eclampsia. Earlier dosing regimens used lower total doses of magnesium sulfate due to concerns about toxicity (10) (11) (12) ; however, these doses were gradually increased in the quest for a greater therapeutic effect (12, 13) . The superiority of magnesium sulfate in the management of eclampsia has been demonstrated against placebo and other anticonvulsants (14) (15) (16) (17) .
Although different magnesium sulfate regimens have been tested, two dosing regimens are internationally recommended and widely used (13, 18) . The Pritchard regimen is a predominantly intramuscular (IM) regimen given as a loading dose of 4 g intravenously (IV) and 5 g IM into each buttock followed by a maintenance dose of 5 g IM every 4 h (19) . This regimen is popular in resource-limited settings where IV administration of magnesium sulfate may not be feasible (13) . However, it is associated with pain and a higher risk of infection at the injection site (13, 17) , The Zuspan regimen, which is given as a 4-g IV loading dose followed by continuous IV infusion of 1 g/hour, is more commonly used in high-income countries (20) (21) (22) . Neither of these regimens, or any other regimen, has been based on standard exposure-response pharmacological studies. Consequently, the optimal dosing regimen of magnesium sulfate is not known.
Some studies have suggested that a lower total dose or even a loading dose-only regimen may be as effective as the standard regimen for managing preeclampsia and eclampsia (23) (24) (25) (26) . If true, this could have a significant impact on the prevention and management of preeclampsia and eclampsia globally, as the currently recommended dosing regimens are faced with implementation challenges for a number of reasons: cost, availability, complexity of administration, need for clinical and or laboratory monitoring, risk of toxicity and the need for an antidote and services to deal with overdose or other complications (27) (28) (29) .
A Cochrane review analyzed data from six randomized controlled trials of alternative magnesium sulfate regimens; however, the evidence was insufficient to establish whether alternative regimens are as efficacious and safe as standard regimens (13) . Within this context, an analysis of the available non-randomized studies is required to capture all available evidence on comparative benefits and harms that could inform future trials of alternative magnesium sulfate regimens. We performed a systematic review to assess available data from non-randomized studies on the comparative efficacy and safety of alternative magnesium sulfate regimens when used for the management of preeclampsia and eclampsia. The findings of our review were expected to complement current evidence from the Cochrane review and inform further efforts to simplify a magnesium sulfate regimen for treatment of preeclampsia and eclampsia.
Material and methods
A protocol was developed in 2013 to address the above aim. The databases searched included Medline, EMBASE, Popline, CINAHL, Global Health Library, African Index Medicus, Biological abstract, BIOSIS. The search was first performed on 16 October 2013, and updated on 26 September 2014 (Appendix S1). No date or language restrictions were used. Additionally, the reference lists of all eligible studies as well as other relevant systematic reviews (13, 18) were reviewed to identify additional studies.
Studies eligible for inclusion were quasi-randomized clinical trials, cohort studies, case-controls studies and cross-sectional studies. Studies were excluded if they were satisfactorily randomized -as distinct from quasi-randomized studies. The population of interest was women with preeclampsia or eclampsia, regardless of single or multiple pregnancy, or time of onset of preeclampsia (antepartum, intrapartum or postpartum). Interventions included any clearly described magnesium sulfate dosing regimen. Control groups were any regimen which was clearly described (including Pritchard and Zuspan regimens). Studies were excluded if there was no comparison group.
Key Message
Non-randomized studies comparing alternative magnesium sulfate dosing regimens for treating preeclampsia and eclampsia are scarce. Lower-dose or bolus-only dosing regimens of magnesium sulfate may be as safe as conventional regimens, but further research is required.
The title and abstracts of all the captured studies were compiled then manually reviewed for duplicates. Titles and abstracts were then screened for eligibility based on inclusion and exclusion criteria, and those potentially relevant were reviewed in full text. The whole process was undertaken with two reviewers overseeing each component of the screening independently and a third reviewer to resolve disagreement. Foreign language articles were reviewed in the same fashion with the assistance of online translation services, where necessary. Once the included studies were identified, data was extracted using a pro forma by one author, cross-checked by another. This captured a range of information including basic study details, patient demographics, primary and secondary outcomes, and details for quality assessment.
The primary outcomes selected were the same as those in the Cochrane review (13) : eclampsia or recurrent seizures, severe maternal morbidity (including respiratory depression, respiratory arrest, cardiac arrest, pneumonia, coagulopathy, renal failure, liver failure, pulmonary edema, stroke, admission to intensive care unit or as defined by authors of primary studies), adverse effects of intervention (including evidence of toxicity -respiratory depression, need for calcium gluconate, stopping or reduced treatment due to toxicity or side effects) or side effects of magnesium sulfate (nausea or vomiting, flushing of the skin, drowsiness, confusion, muscle weakness, problem at injection site), fetal and/or neonatal death (any death up to 28 days, including stillbirths). Secondary outcomes were: maternal mortality, neonatal morbidity (Apgar score <7 at five minutes, need for intubation at delivery, ventilation, seizures, admission to neonatal special care nursery), mode of delivery (for antepartum or intrapartum preeclampsia), induction or augmentation of labor, abruptio placentae, postpartum hemorrhage, economic outcome measures, patient and provider acceptability.
Quality assessment was performed using an adapted version of the Newcastle-Ottawa Scale (NOS) (30) . We chose to use NOS as it is a widely accepted tool for appraising the quality of non-randomized studies and is recommended by the Cochrane Collaboration (31). This scale was implemented using the conventional criteria, judging each component to be of "low", "high" or "unclear" risk of bias (30) . Due to recent criticisms of this scoring tool which suggest that the parameters of NOS may be too arbitrary (32, 33) , the quality assessment was extended to include certain elements of the STROBE quality assessment tool which are not covered by NOS, specifically the reporting of all outcome measures and the authors' discussion of potential sources of bias (34) . These two additional items were judged by the authors to be of "low", "high" or "unclear" risk of bias based on STROBE guidance (34) . All assessments were made by two authors, with a third author available for disputes.
The extracted data were initially compiled in a Microsoft Excel file. REVMAN software was used to compile data and conduct meta-analyses where comparison groups were judged by the review team to be sufficiently comparable. Analysis conducted with REVMAN used extracted data for odds ratios (ORs) considering effects as random. The data extracted were unadjusted and no adjusted estimates were obtained. Outcome measures were expressed as unadjusted ORs with 95% confidence intervals (CI). A decision was made a priori to judge statistical heterogeneity as low where the I 2 score was less than 40%. This publication was written following the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) Statement (35) The potential comparisons are similar to those in the Cochrane review: loading dose only versus loading dose plus maintenance, lower-dose regimens versus standard regimens, reduced duration of maintenance dose versus standard duration or two regimens, of which neither are Pritchard or Zuspan (13) . We planned to analyze data for preeclampsia and eclampsia separately. However, due to paucity of data, these groups were combined for the purpose of meta-analysis.
Results
The search strategy identified 6178 citations. After the duplicates were removed, 3901 abstracts were assessed and 248 potentially relevant studies were reviewed in full text ( Figure 1 ). The abstract of three citations could not be found despite exhaustive efforts, although their titles did not indicate relevance to the question of the review. Including the yield from the review of reference lists (one additional study), five studies met our inclusion criteria and were included in this review.
The characteristics of the included studies are reported in Table 1 . The definition of preeclampsia was not always clear; the definition of hypertension in pregnancy varied from 140/90 (36) to 160/110 mmHg (37) and was not stated in two studies (38, 39) . Exclusion criteria were not stated in two of the studies (39, 40) , and the other three studies excluded women with non-eclamptic seizures (36) (37) (38) . The ages of the participants were relatively similar across studies; however, there was significant variation in both parity and severity of preeclampsia or eclampsia. Three studies recruited women with eclampsia only (36, 38, 39) , and two studies recruited women with preeclampsia or eclampsia (37, 40) . Three studies did not report any details of their approach to dealing with multiple pregnancies within their study design (37, 39, 40) . Of those that did, Chowdhury et al. (38) did not exclude women with a multiple pregnancy, although further details were not provided. Seth et al. (36) did not refer to multiple pregnancy in its inclusion and exclusion criteria but reported the inclusion of three sets of twins. No study stratified outcomes based on single or multiple birth or reported on statistical adjustment for multiplicity. Three of the studies were conducted in India (36, 38, 39) , one in Nigeria (37) and one in Pakistan (40), all LMICs. Table 1 shows the range of treatment regimens used. Four studies used the Pritchard regimen in the control group (36) (37) (38) 40) . The experimental groups for these studies were all lower-dose regimens; however, the total dose in the first 24 h in these regimens varied significantly from 9 (36) to 35 g (37) The Seth et al. (36) study had three arms: (Group I) standard Pritchard regimen; (Group II) low-dose regimen, 4 g IV loading dose then 2 g IM every three hours; and (Group III) trialing a loading dose-only regimen, 4 g IV plus 5 g IM in one buttock (36) . The Mahajan et al. (39) study compared two different low-dose regimens; both groups received the same maintenance dose of 4 g IM magnesium sulfate; however, one received a loading dose of 2 g IV magnesium sulfate plus 4 g IM, whereas the other group received 2 g IV plus 8 g IM. That study had a substantial selection bias, as all patients in the first group had come to the treating hospital via a peripheral center, which delayed treatment initiation by three to six hours (39) .
The assessment of quality is presented in Figure 2 and Table 2 . Examining the NOS criteria in isolation, the quality of included studies was generally high and three of the five studies were rated as low risk of bias in all domains (36, 38, 40) and one study was rated at low risk of bias on all domains apart from comparability of age and parity (37) . However, the additional STROBE criteria (Figure 2 ) suggested that none of the included studies had adequately reported potential sources of bias. The Mahajan et al. (39) study was rated as poor across both NOS and STROBE criteria. Their study design was inherently prone to bias, in that one group had attended another hospital and had been given either diazepam or promethazine prior to transport, and then received a 6-g magnesium sulfate total loading dose at the study hospital. The other group presented directly to the study hospital and received a 10-g magnesium sulfate total loading dose only. Additionally, outcome assessment was incomplete and the study did not discuss potential biases. Using the GRADE approach, the quality of evidence was rated low or very low.
With the available data, two comparisons were possible: (1) low-dose regimens, defined as s out of any regimen with a total 24-h dose less than the standard regimens, versus standard regimens; (2) loading dose only versus loading dose plus maintenance. A decision was made to aggregate the Seth et al. (36) low dose data (Group II and Group III) into one composite group for the purposes of assessing the safety of all low-dose regimens, and then using a subset of this data in the loading dose-only analysis (Group III only). Due to lack of data, this review was not able to compare regimens according to duration of maintenance dose.
Low dose vs. standard regimens
For this comparison, four studies were included, with 899 women in total (36) (37) (38) 40) : two studies of eclampsia (36, 38) , one of preeclampsia (40) and one which looked at both conditions (37) . Each study compared the Pritchard regimen (representing a 39-g total dose over the first 24 h) with lower-dose regimens; however, the total dose in the first 24 h varied widely between studies. In the Chowdhury et al. (38) from the Okusanya et al. (37) study was not available for all outcomes; however, where data was available it was included in the meta-analysis. Where it was included, sensitivity analyses were conducted to assess its overall effect. Data was only available for seizures post-treatment initiation, severe maternal morbidity, fetal and/or neonatal mortality, maternal mortality and cesarean section rates ( Figure 3 2 = 0%). The odds of cesarean section between groups was similar (OR 0.64, 95%CI 0.31-1.32, p = 0.23, 695 women, three studies), as were the odds of forceps or ventouse deliveries (OR 0.82, 95% CI 0.51-1.30, p = 0.40, 595 women, two studies). The low-dose regimens had significantly fewer women with loss of deep tendon reflexes, a sign of overdose (OR 0.09, 95% CI 0.01-0.72, p = 0.02, 696 women, two studies).
Loading dose only vs. loading dose plus maintenance dose regimens
Two studies included data on loading dose-only regimens compared with loading dose plus maintenance, both using the Pritchard regimen as the control (Figure 4) (36, 40) . One studied eclampsia (36) and the other studied preeclampsia (40) . Seizures were no more frequent in the loading dose-only groups than the control group (OR 0.99, 95% CI 0.22-4.50, p = 0.99, 146 women, two studies). For maternal morbidity and mortality, the Shoaib et al. 
Discussion
This systematic review reports on evidence from non-randomized studies comparing alternative regimens of magnesium sulfate for the management of preeclampsia and eclampsia with standard regimens. Although the available evidence was scarce, two findings emerged from our analysis. First, when comparing the low-dose regimens with the standard regimen, the rates of several maternal and perinatal outcomes were not significantly different between groups. Secondly, we found that loading doseonly regimens were not associated with worse maternal and perinatal outcomes compared with standard regimens. However, these findings must be interpreted cautiously in light of the overall paucity of evidence (both in number of studies and outcomes available in included studies) and potential biases among the included studies. When the critical outcomes were evaluated using GRADE criteria, the quality of evidence was rated to be low or very low (Tables 3 and 4) . Although this review suggests that a reduced-dose magnesium sulfate regimen may not be inferior to existing regimens, further research (such as a randomized controlled trial) is clearly needed. While maternal morbidity was lower in the three studies using low-dose regimens, the mechanism of this was unclear. Notably, 85% of the participants in this meta- analysis came from one study (38) and one study had no events in either group for several outcomes (40) . Also, in the Chowdhury et al. (38) study, maternal morbidity was not clearly defined. With regard to the fetal and/or neonatal mortality outcome, interpretation is difficult due to the impact of the Okusanya et al. (37) study, which reversed the relation. The significance of this is unclear, although neonatal magnesium levels are known to correlate with maternal dosing of magnesium (41, 42) and exposure to magnesium sulfate is associated with NICU admission in a dose-response relationship (43) . However, this trend was not found in other key studies including the MAGPIE trial (13, 17, 44, 45) . For both of these outcomes, the presence of multiple pregnancies may have been an important confounder. This systematic review had several strengths. It followed the standard systematic review protocol based around a thorough search strategy and every effort was made to retrieve all possible studies of relevance (31) . By searching several international databases with no time or language restrictions, we feel that we have minimized the chances that there are other studies relevant to this specific systematic review that might have been missed. As such, that this systematic review and the 2010 Cochrane review included only a small number of studies likely reflects a general paucity of data on the topic. The review also had some limitations. Firstly, due to paucity of data we chose to combine women with either eclampsia or preeclampsia into one group in an effort to perform meta-analysis. Although the two conditions exist on the same spectrum, the pharmacokinetics of magnesium sulfate in these two conditions may be different, and so too may the clinical efficacy of the stated treatment regimens. Secondly, the primary studies included in this review had relatively small sample sizes and few events for most outcomes, resulting in a low certainty of our findings. This, in addition to the fact that all studies are non-randomized, meant that results should be interpreted with caution. Of the studies included, the settings and ages were similar; however, there was variation in parity and definition of preeclampsia, as well as dosing regimens, which raises concerns over the heterogeneity of these studies. Adjusted estimates were not available to mitigate some of this heterogeneity. In the context of the current literature, this systematic review supports the argument that a lower dosing schedule of magnesium sulfate could potentially be as safe and effective as current regimens, and we conclude that further research is warranted. Our findings add to the existing Cochrane review, which was unable to draw firm conclusions on either low-dose regimens or loading dose-only regimens, due to only finding one randomized trial relevant to each of these comparisons (13) . Of note, our search strategy also found a study of 265 women with eclampsia or preeclampsia which compared initiation of magnesium sulfate in the community to initiation at hospital (46) . It did not meet any of our predetermined comparison groups and was excluded; however, it is a topic of interest previously identified in the Cochrane The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI, Confidence interval; OR, Odds ratio. (46) . We agree with the conclusion of the Cochrane review that a randomized controlled trial of a simplified magnesium sulfate regimen for preeclampsia and eclampsia is required to establish the optimal dosing regimen (13) . Such a regimen would have practical advantages such as reduced cost, reduced complexity of administration and reduced monitoring requirements, as well as potentially reduced risk of side effects. These are most significant in LMICs, where geographical, financial, infrastructural and other barriers to life-saving obstetric care can be significant. Simplified dosing can also potentially facilitate taskshifting to improve coverage and access, and thus save lives. Although we can make no firm conclusion on the structure of a simplified dosing regimen, pharmacokinetic/pharmacodynamic studies should be done to carefully explore this in further detail. Extending from these, a high quality multicenter RCT is required to determine whether a low-dose magnesium sulfate regimen is as safe as the conventional regimens.
Conclusion
In spite of the considerable variation in the dosage regimens of magnesium sulfate employed for treatment of preeclampsia and eclampsia in clinical practice, this review shows that non-randomized comparisons of regimens are scarce. Only five studies were available and no data available for several important maternal and perinatal outcomes. Given this uncertainty, further research is required to establish whether a simplified dosing regimen could be safely used to manage preeclampsia and eclampsia.
